Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Roy Blum, Ph.D.

Profile Picture

New York University, New York CityPostdoc06/2013Muscle Epigenetics
New York University, New York CityPostdoc07/2008Prostate Stem Cells
Tel Aviv University, Tel AvivP.hD.07/2007System Biology
Tel Aviv University, Tel AvivM.Sc.08/2001Neurobiochemistry
Tel Aviv University, Tel AvivB.Sc.08/1999Biology (Extended Program)
John Bryce Training Center, Tel Aviv10/1997Computer Programming
Dan David Scholarship award


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Rosenberg M, Blum R, Kesner B, Aeby E, Garant JM, Szanto A, Lee JT. Motif-driven interactions between RNA and PRC2 are rheostats that regulate transcription elongation. Nat Struct Mol Biol. 2021 01; 28(1):103-117. PMID: 33398172.
    Citations:    Fields:    Translation:AnimalsCells
  2. Jégu T, Blum R, Cochrane JC, Yang L, Wang CY, Gilles ME, Colognori D, Szanto A, Marr SK, Kingston RE, Lee JT. Xist RNA antagonizes the SWI/SNF chromatin remodeler BRG1 on the inactive X chromosome. Nat Struct Mol Biol. 2019 02; 26(2):96-109. PMID: 30664740.
    Citations: 15     Fields:    Translation:AnimalsCells
  3. Carrette LLG, Blum R, Ma W, Kelleher RJ, Lee JT. Tsix-Mecp2 female mouse model for Rett syndrome reveals that low-level MECP2 expression extends life and improves neuromotor function. Proc Natl Acad Sci U S A. 2018 08 07; 115(32):8185-8190. PMID: 30038001.
    Citations: 8     Fields:    Translation:HumansAnimals
  4. Rosenberg M, Blum R, Kesner B, Maier VK, Szanto A, Lee JT. Denaturing CLIP, dCLIP, Pipeline Identifies Discrete RNA Footprints on Chromatin-Associated Proteins and Reveals that CBX7 Targets 3' UTRs to Regulate mRNA Expression. Cell Syst. 2017 10 25; 5(4):368-385.e15. PMID: 29073373.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  5. Wang CY, Froberg JE, Blum R, Jeon Y, Lee JT. Comment on "Xist recruits the X chromosome to the nuclear lamina to enable chromosome-wide silencing". Science. 2017 06 16; 356(6343). PMID: 28619887.
    Citations: 1     Fields:    Translation:Cells
  6. Blum R. Stepping inside the realm of epigenetic modifiers. Biomol Concepts. 2015 Apr; 6(2):119-36. PMID: 25915083.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  7. Blum R. Activation of muscle enhancers by MyoD and epigenetic modifiers. J Cell Biochem. 2014 Nov; 115(11):1855-67. PMID: 24905980.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  8. Jones CL, Bhatla T, Blum R, Wang J, Paugh SW, Wen X, Bourgeois W, Bitterman DS, Raetz EA, Morrison DJ, Teachey DT, Evans WE, Garabedian MJ, Carroll WL. Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J Biol Chem. 2014 Jul 25; 289(30):20502-15. PMID: 24895125.
    Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
  9. Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T, Morrison DJ, Raetz EA, Carroll WL. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Pediatr Blood Cancer. 2014 Oct; 61(10):1779-85. PMID: 24976218.
    Citations: 7     Fields:    Translation:HumansCells
  10. Cheng J, Blum R, Bowman C, Hu D, Shilatifard A, Shen S, Dynlacht BD. A role for H3K4 monomethylation in gene repression and partitioning of chromatin readers. Mol Cell. 2014 Mar 20; 53(6):979-92. PMID: 24656132.
    Citations: 82     Fields:    Translation:HumansAnimalsCells
  11. Blum R, Kloog Y. Metabolism addiction in pancreatic cancer. Cell Death Dis. 2014 Feb 20; 5:e1065. PMID: 24556680.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  12. Blum R, Dynlacht BD. The role of MyoD1 and histone modifications in the activation of muscle enhancers. Epigenetics. 2013 Aug; 8(8):778-84. PMID: 23880568.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  13. Blum R, Vethantham V, Bowman C, Rudnicki M, Dynlacht BD. Genome-wide identification of enhancers in skeletal muscle: the role of MyoD1. Genes Dev. 2012 Dec 15; 26(24):2763-79. PMID: 23249738.
    Citations: 70     Fields:    Translation:AnimalsCells
  14. Vazquez-Cintron EJ, Monu NR, Burns JC, Blum R, Chen G, Lopez P, Ma J, Radoja S, Frey AB. Protocadherin-18 is a novel differentiation marker and an inhibitory signaling receptor for CD8+ effector memory T cells. PLoS One. 2012; 7(5):e36101. PMID: 22567129.
    Citations: 5     Fields:    Translation:AnimalsCells
  15. Asp P, Blum R, Vethantham V, Parisi F, Micsinai M, Cheng J, Bowman C, Kluger Y, Dynlacht BD. Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proc Natl Acad Sci U S A. 2011 May 31; 108(22):E149-58. PMID: 21551099.
    Citations: 144     Fields:    Translation:HumansAnimalsCells
  16. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL. Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways. PLoS One. 2010 Sep 30; 5(9). PMID: 20941365.
    Citations: 14     Fields:    Translation:AnimalsCells
  17. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL. Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS One. 2009 May 29; 4(5):e5722. PMID: 19478945.
    Citations: 37     Fields:    Translation:HumansAnimalsCells
  18. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov. 2008 Jan; 3(1):31-47. PMID: 18289122.
    Citations: 33     Fields:    Translation:HumansAnimalsCells
  19. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res. 2007 Apr 01; 67(7):3320-8. PMID: 17409441.
    Citations: 23     Fields:    Translation:HumansCells
  20. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. . 2006 Sep; 5(9):2337-47. PMID: 16985068.
    Citations: 13     Translation:HumansCells
  21. Blum R, Nakdimon I, Goldberg L, Elkon R, Shamir R, Rechavi G, Kloog Y. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. Int J Cancer. 2006 Aug 01; 119(3):527-38. PMID: 16496386.
    Citations: 6     Fields:    Translation:HumansCells
  22. Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y, Pinkas-Kramarski R. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol. 2006 Aug 14; 72(4):427-36. PMID: 16780807.
    Citations: 18     Fields:    Translation:HumansCells
  23. Blum R, Kloog Y. Tailoring Ras-pathway--inhibitor combinations for cancer therapy. Drug Resist Updat. 2005 Dec; 8(6):369-80. PMID: 16356760.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  24. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005 Feb 01; 65(3):999-1006. PMID: 15705901.
    Citations: 63     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Blum's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (167)
Co-Authors (8)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.